| Yu, Lei |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis |
|
|
| Recruiting | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 06/28 | 10/28 | | |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
NCT06363825: A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 57 | RoW | camrelizumab, apatinib | Fujian Medical University | Advanced Hepatocellular Carcinoma | 04/26 | 05/27 | | |
NCT05919680: A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). |
|
|
| Recruiting | 2 | 36 | US | NST-6179 Part A, NST-6179 Part B, Matched Placebo | NorthSea Therapeutics B.V. | Intestinal Failure Associated Liver Disease | 06/25 | 06/25 | | |
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B |
|
|
| Not yet recruiting | 1/2 | 162 | RoW | TQA3038 injection/placebo, Nucleotide drugs Control group | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B, Chronic | 09/26 | 09/26 | | |
NCT04211805: Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B |
|
|
| Recruiting | N/A | 450 | RoW | Tenofovir Alafenamide 25 MG for arm (A), HBIg 200 IU im for infants, HBV vaccine 10 ug im for infants, Tenofovir Disoproxil Fumarate 300mg for arm (B) | New Discovery LLC | Hepatitis B, Chronic, Pregnancy Related | 09/21 | 09/21 | | |
